Last reviewed · How we verify
2% mupirocin ointment
At a glance
| Generic name | 2% mupirocin ointment |
|---|---|
| Also known as | Bactroban, Bacitracin |
| Sponsor | Washington University School of Medicine |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Effect of S. Aureus Skin Decolonization on Disease Severity in Atopic Dermatitis Patients (PHASE4)
- Staph Household Intervention for Eradication (SHINE) (PHASE4)
- STaph Aureus Resistance-Treat Early and Repeat (STAR-TER) (PHASE2)
- Bacterial Decolonization Plus Intraoperative Angiography for Soft Tissue Sarcomas Receiving Preoperative Radiotherapy (CONCERTO) (PHASE2)
- Bacterial Decolonization Within Dyads (NA)
- The Effect of Bacterial Decolonization Before Skin Cancer Surgery on Infection Rate of Lower Extremity Wounds Left Open to Heal (PHASE3)
- Decolonization to Reduce After-Surgery Events of Surgical Site Infection (PHASE4)
- Surgical Wound Infection Prevention Bundle in Patients Undergoing Coronary Bypass Graft Surgery (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- 2% mupirocin ointment CI brief — competitive landscape report
- 2% mupirocin ointment updates RSS · CI watch RSS
- Washington University School of Medicine portfolio CI